These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
541 related articles for article (PubMed ID: 30414056)
1. Treatment of apixaban- and rivaroxaban-associated major bleeding using 4-factor prothrombin complex concentrate. Sheikh-Taha M Intern Emerg Med; 2019 Mar; 14(2):265-269. PubMed ID: 30414056 [TBL] [Abstract][Full Text] [Related]
2. Reversal of Apixaban and Rivaroxaban Using Activated Prothrombin Complex Concentrates in Patients with Major Bleeding. Sheikh-Taha M; Crawley RM Am J Cardiovasc Drugs; 2020 Jun; 20(3):295-299. PubMed ID: 31709499 [TBL] [Abstract][Full Text] [Related]
3. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages. Pham H; Medford WG; Horst S; Levesque M; Ragoonanan D; Price C; Colbassani H; Piper K; Chastain K Am J Emerg Med; 2022 May; 55():38-44. PubMed ID: 35272069 [TBL] [Abstract][Full Text] [Related]
4. Prothrombin Complex Concentrate before Urgent Surgery in Patients Treated with Rivaroxaban and Apixaban. Barzilai M; Kirgner I; Steimatzky A; Salzer Gotler D; Belnick Y; Shacham-Abulafia A; Avivi I; Raanani P; Yahalom V; Nakav S; Varon D; Yussim E; Bachar GN; Spectre G Acta Haematol; 2020; 143(3):266-271. PubMed ID: 31610537 [TBL] [Abstract][Full Text] [Related]
5. Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products. Castillo R; Chan A; Atallah S; Derry K; Baje M; Zimmermann LL; Martin R; Groysman L; Stern-Nezer S; Minokadeh A; Nova A; Huang W; Cang W; Schomer K J Thromb Thrombolysis; 2021 Jan; 51(1):151-158. PubMed ID: 32500220 [TBL] [Abstract][Full Text] [Related]
6. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis. Costa OS; Connolly SJ; Sharma M; Beyer-Westendorf J; Christoph MJ; Lovelace B; Coleman CI Crit Care; 2022 Jun; 26(1):180. PubMed ID: 35710578 [TBL] [Abstract][Full Text] [Related]
7. Low Risk of Traumatic Intracranial Hematoma Expansion with Factor Xa Inhibitors without Andexanet Reversal. Maragkos GA; Nelton EB; Richter S; Stippler M World Neurosurg; 2020 Oct; 142():e95-e100. PubMed ID: 32561488 [TBL] [Abstract][Full Text] [Related]
8. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Majeed A; Ågren A; Holmström M; Bruzelius M; Chaireti R; Odeberg J; Hempel EL; Magnusson M; Frisk T; Schulman S Blood; 2017 Oct; 130(15):1706-1712. PubMed ID: 28835439 [TBL] [Abstract][Full Text] [Related]
9. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage. Vestal ML; Hodulik K; Mando-Vandrick J; James ML; Ortel TL; Fuller M; Notini M; Friedland M; Welsby IJ J Thromb Thrombolysis; 2022 Jan; 53(1):167-175. PubMed ID: 34101050 [TBL] [Abstract][Full Text] [Related]
10. Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study. Schulman S; Gross PL; Ritchie B; Nahirniak S; Lin Y; Lieberman L; Carrier M; Crowther MA; Ghosh I; Lazo-Langner A; Zondag M; Thromb Haemost; 2018 May; 118(5):842-851. PubMed ID: 29564837 [TBL] [Abstract][Full Text] [Related]
11. Andexanet alfa effectiveness and safety versus four-factor prothrombin complex concentrate (4F-PCC) in intracranial hemorrhage while on apixaban or rivaroxaban: A single-center, retrospective, matched cohort analysis. Parsels KA; Seabury RW; Zyck S; Miller CD; Krishnamurthy S; Darko W; Probst LA; Latorre JG; Cwikla GM; Feldman EA Am J Emerg Med; 2022 May; 55():16-19. PubMed ID: 35245776 [TBL] [Abstract][Full Text] [Related]
12. Non-activated prothrombin complex concentrates for major bleeding in patients on apixaban and rivaroxaban. Sheikh-Taha M Intern Emerg Med; 2020 Sep; 15(6):1123-1124. PubMed ID: 31664661 [No Abstract] [Full Text] [Related]
13. Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages. Barra ME; Das AS; Hayes BD; Rosenthal ES; Rosovsky RP; Fuh L; Patel AB; Goldstein JN; Roberts RJ J Thromb Haemost; 2020 Jul; 18(7):1637-1647. PubMed ID: 32291874 [TBL] [Abstract][Full Text] [Related]
14. Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates. Panos NG; Cook AM; John S; Jones GM; Circulation; 2020 May; 141(21):1681-1689. PubMed ID: 32264698 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding. Arachchillage DRJ; Alavian S; Griffin J; Gurung K; Szydlo R; Karawitage N; Laffan M Br J Haematol; 2019 Mar; 184(5):808-816. PubMed ID: 30515764 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Activated Prothrombin Complex Concentrate for Reversal of the Anticoagulant Effect of Apixaban and Rivaroxaban in Patients with Major Bleeding. Sheikh-Taha M; Clark HL; Crawley RM Clin Drug Investig; 2023 Nov; 43(11):883-888. PubMed ID: 37882941 [TBL] [Abstract][Full Text] [Related]
18. Emergent reversal of oral factor Xa inhibitors with four-factor prothrombin complex concentrate. Lipari L; Yang S; Milligan B; Blunck J Am J Emerg Med; 2020 Dec; 38(12):2641-2645. PubMed ID: 33041150 [TBL] [Abstract][Full Text] [Related]
19. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study. Smith MN; Deloney L; Carter C; Weant KA; Eriksson EA J Thromb Thrombolysis; 2019 Aug; 48(2):250-255. PubMed ID: 30941571 [TBL] [Abstract][Full Text] [Related]
20. Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage. Lipski M; Pasciolla S; Wojcik K; Jankowitz B; Igneri LA J Thromb Thrombolysis; 2023 Apr; 55(3):519-526. PubMed ID: 36566473 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]